Guoqin Fu,Wei Ding,Bo Yin,Chao Yang,Cuiqin Wang,Yong Dou,Ruiling Wang
申请号：
US16626934
公开号：
US20200131212A1
申请日:
2018.08.15
申请国别(地区):
US
年份:
2020
代理人:
摘要：
Provided are a compound for treating metabolic diseases having the structure as shown in formula (I) or formula (II), or a racemate, stereoisomer, geometric isomer, tautomer, solvate, hydrate, metabolite, pharmaceutically acceptable salt or prodrug thereof. The compound is an activator of FXR and/or a TGR5 receptor, and thus has the activity of activating FXR and/or a TGR5 receptor, and can be used in the preparation of drugs for treating chronic liver diseases, metabolic diseases or portal hypertension.
